The funding will help support our current clinical trial evaluating the safety and efficacy of ViaCyte's PEC - Direct product candidate, which is in development as
a potential cure for patients with high - risk type 1 diabetes.
Not exact matches
Current treatments include transplanting
patients with donor HSC, which is a
potential cure for SCD, but due to the serious risks of rejection, only a small number of
patients have undergone this procedure and it is usually restricted to children with severe symptoms.
Achieving such a long - term goal may lead to a
potential cure, not only a treatment,
for those
patients.»
The company's lead PEC - DirectTM product candidate is entering clinical development as a
potential functional
cure for patients with type 1 diabetes with the highest risk of life threatening acute complications.
After implantation, the cells are expected to mature into the full complement of islet cells, including insulin - producing beta cells, offering a
potential functional
cure for patients with high - risk type 1 diabetes.
Used with concomitant maintenance immune suppression therapy, the PEC - Direct product has the
potential of delivering a sustained, functional
cure for patients with type 1 diabetes who are at high risk
for acute life - threatening complications.
Using cloning technology to derive embryonic stem cells genetically identical to a
patient is potentially very important, not only to provide a source of cells that may be used to
cure patients, but also to allow
for genetic disease to be studied and
potential drug treatments to be explored in the laboratory.
This will cover all our bases
for potential cures and will allow us to treat all
patients who are looking to have a happier, healthier life.